

5th Congress of the European Academy of Neurology

Oslo, Norway, June 29 - July 2, 2019

Hands-on Course 3/7

Transcranial magnetic stimulation(Level 1)

Letizia Leocani Milan, Italy

Email: letizia.leocani@hsr.it



Oslo, June 29, 2019 Hands-on Course – Level 1

Hands-on course

Transcranial Magnetic Stimulation – TMS

Letizia Leocani

Neurology Dep.t University Hospital San Raffaele Milan - Italy

DISCLOSURES (alphabetical order):

Letizia Leocani:

- Advisory board: Abbvie, Biogen, Merck Serono, Novartis
- <u>Travel support</u>: Almirall, Biogen, Genzyme, Merck Serono, Novartis, Teva
- Research support: Almirall, Biogen, Merck Serono, Novartis
- Speakers bureau: Almirall, Biogen, Excemed, Merck Serono, Novartis, Teva

key learning objectives

- how to:
 - Screen for safety limitations
 - record motor evoked potentials
 - measure motor threshold
 - measure central motor conduction time
 - measure silent period (research)







PHYSIOLOGICAL BASIS OF TMS

- A single suprathreshold TMS pulse with a large round coil produces a series of descending volleys (multiple I-waves and possibly a D-wave), indicating strong repetitive activation of the corticospinal neurons
- Each descending volley induces glutamate release in cortico-MN synapses leading to a depolarization at the postsynaptic cell membrane
- The glutamate release triggered by each volley sums up temporally and spatially; if the volleys are strong enough to exceed the firing threshold, they **trigger an action potential** (AP) in the spinal MN
- These APs propagate along the peripheral motor axons inducing a motor response that can be recorded as the MEP



TECHNICAL PRINCIPLES OF TMS

	TES	TMS
Direction of E	Parallel & perpendicular	Parallel
Sensitive to skull conductivity	Yes	No
Neuronal activation	Direct (D waves)	Indirect (I waves)
Resistance to anaesthetics	High	Low
Painful	Yes	No
Hetric Field, E	D I D I 2ms	Magnetic field, B Coll Electric field, E









Cortical silent period (CSP)

Suprathreshold stimulus during muscular contraction interrupts the voluntary EMG activity. The higher the stimulus intensity, the longer the silent period

Trompetto et al 2001



TECHNICAL PRINCIPLES OF TMS STIMULUS WAVEFORM Two different pulse waveforms are commonly used for clinical TMS: • monophasic pulse • biphasic pulse Magstim 200² The 200² is a single pulse, monophasic stimulator used for cortical and peripheral stimulation. Read more Magstim BiStim² The BiStim² is an extension of the 200². Two of the single pulse systems are combined through a connecting module, so that paired pulses can be delivered through one coil. Read more Magstim Rapid² The Magstim Rapid² is a system capable of high frequency, repetitive transcranial magnetic stimulation (rTMS). It is ideal for therapeutic applications as well as a wide variety of research fields. Read more











	TECHNICAL PRINCIPLES OF TMS
It is recom diagnostic	mended to use a large round coil for TMS :
	l positioning over M1, because coil s a larger cortical volume
	pth penetration, which facilitate TMS of notor leg area
	on of M1 is less susceptible to the minor n coil position

Author	Threshold determination	N.stimuli	Definition
Rossini/Rothwell 1994	relative frequency method	75	Lowest stimulus intensity (% MSO) inducing 5 MEP in 10 trials
Mills and Nithi, 1997	Two-threshold method	48	Mean of lower and upper threshold. LT: highest stimulus intensity at which no motor response is evoked in 10 trials. UT: lowest stimulus intensity at which MEP responses are evoked in all 10 trials
Awiszus, 2003	Adaptive method	14-7	Parameter Estimation by Sequential Testing (PEST) and Maximum Likelihood regression Motor Threshold Assessment Tool, version 2.0: http://www.clinicalresearcher.org/softwa re
Qui, 2011	Bayesian adaptive method	3-7	Parameter Estimation by Sequential Testing (PEST) and Maximum Likelihood regression. 3 when using subject-specific priors

THRESHOLD FOR CORTICOMOTOR EXCITATION

• Original method (Rossini et al., 1994)

CMT is defined as the lowest stimulus intensity (given as % of MSO) that is required to induce a MEP in 5 out of 10 trials

- MEP \geq 50 μ V in relaxed muscle
- MEP \ge 200 μ V during tonic contraction of the target muscle

• Slightly modified method

CMT is defined as the lowest stimulus intensity (given as % of MSO) at which TMS evokes a MEP in at least 5 out of 10 trials

I. TMS should start with a subthreshold intensity of stimulation

II. Stimulus intensity is gradually increased in steps of 5% MSO until TMS consistently evokes MEPs with peak-to-peak amplitude > 50 μ V in each trial

III. Then stimulus intensity is gradually lowered in steps of 1% MSO until less than 5 positive responses out of 10 trials are recorded

IV. This stimulus intensity plus 1 is then defined as CMT

THRESHOLD FOR CORTICOMOTOR EXCITATION

- Cortical motor threshold (CMT) for the target muscle reflects the excitability of the whole corticomotor projections, including cortical and spinal level
- Two methods for determining CMT in clinical practice:
 - 1. Resting Motor Threshold (RMT)

determined with the target muscle being completely relaxed

method commonly employed in clinical practice

2. Active Motor Threshold (AMT)

obtained during a slight tonic contraction of the target muscle:

10-20% of the maximal strength

• CMT is not a static measure but is subject to state-dependent fluctuations which account for some intra-individual variations (individual posture, pharmacological influence, target muscle, sleep-wake cycle, age, CNS maturation, technical setup)

• The diagnostic use of the CMT is limited due to its inter- and intra-individual variability, even in healthy subjects

In spite of these limitations, it **is recommended to integrate CMT measurement** in the overall neurophysiological assessment, and the CMT value, together with the method used for its estimation, **should be listed in the final report**

SAFETY ASPECTS OF SINGLE-PULSE TMS CONTRAINDICATIONS

Although single-pulse TMS is considered to have no significant risk, a **short safety check list should be used to screen patients before they undergo TMS** investigations, including:

- implanted biomedical devices (*absolute c.i.*) (brain stimulation systems, epidural/subdural electrode arrays for cortical stimulation, cochlear implants, infusion pumps, pace-makers)
- history of seizures or syncope (relative c.i.)
- brain diseases or medications associated with increase seizure risk (relativec.i.)
- pregnancy (avoid magnetic nerve root stimulation over the lumbar spine) (relative c.i.)
- age \leq 18 months (mechanical injuries due to excessive coil pressure) (*relative c.i.*)

Metal implants outside the head: because of the rapid attenuation of the induced electromagnetic field with increasing distance from the discharging coil, **there are no safety hazards** in adults carrying metal implants (e.g., prostheses, pumps for drug injection or any other hardware device) at any place in their body outside the head

 (1) Do you have epilepsy or have you ever had a convulsion or a seizure? (2) Have you ever had a fainting spell or syncope? If yes, please describe on which occasion(s)? (3) Have you ever had a head trauma that was diagnosed as a concussion or was associated with loss of consciousness? (4) Do you have any hearing problems or ringing in your ears? (5) Do you have cochlear implants? (6) Are you pregnant or is there any chance that you might be? (7) Do you have metal in the brain, skull or elsewhere in your body (e.g., splinters, fragments, clips, etc.)? If so, specify the type of metal. (8) Do you have a nimplanted neurostimulator (e.g., DBS, epidural/subdural, VNS)? (9) Do you have a medication infusion device? (11) Are you taking any medications? (please list) (12) Did you ever undergo TMS in the past? If so, were there any problems. (13) Did you ever undergo MRI in the past? If so, were there any problems. 			
 describe on which occasion(s)? (3) Have you ever had a head trauma that was diagnosed as a concussion or was associated with loss of consciousness? (4) Do you have any hearing problems or ringing in your ears? (5) Do you have cochlear implants? (6) Are you pregnant or is there any chance that you might be? (7) Do you have metal in the brain, skull or elsewhere in your body (e.g., splinters, fragments, clips, etc.)? If so, specify the type of metal. (8) Do you have an implanted neurostimulator (e.g., DBS, epidural/subdural, VNS)? (9) Do you have a cardiac pacemaker or intracardiac lines? (10) Do you have a medication infusion device? (11) Are you taking any medications? (please list) (12) Did you ever undergo TMS in the past? If so, were there any problems. (13) Did you ever undergo MRI in the past? If so, were there any 			
 concussion or was associated with loss of consciousness? (4) Do you have any hearing problems or ringing in your ears? (5) Do you have cochlear implants? (6) Are you pregnant or is there any chance that you might be? (7) Do you have metal in the brain, skull or elsewhere in your body (e.g., splinters, fragments, clips, etc.)? If so, specify the type of metal. (8) Do you have an implanted neurostimulator (e.g., DBS, epidural/subdural, VNS)? (9) Do you have a cardiac pacemaker or intracardiac lines? (10) Do you have a medication infusion device? (11) Are you taking any medications? (please list) (12) Did you ever undergo TMS in the past? If so, were there any problems. (13) Did you ever undergo MRI in the past? If so, were there any 	0		
 (5) Do you have cochlear implants? (6) Are you pregnant or is there any chance that you might be? (7) Do you have metal in the brain, skull or elsewhere in your body (e.g., splinters, fragments, clips, etc.)? If so, specify the type of metal. (8) Do you have an implanted neurostimulator (e.g., DBS, epidural/subdural, VNS)? (9) Do you have a cardiac pacemaker or intracardiac lines? (10) Do you have a medication infusion device? (11) Are you taking any medications? (please list) (12) Did you ever undergo TMS in the past? If so, were there any problems. (13) Did you ever undergo MRI in the past? If so, were there any 			
 (7) Do you have metal in the brain, skull or elsewhere in your body (e.g., splinters, fragments, clips, etc.)? If so, specify the type of metal. (8) Do you have an implanted neurostimulator (e.g., DBS, epidural/subdural, VNS)? (9) Do you have a cardiac pacemaker or intracardiac lines? (10) Do you have a medication infusion device? (11) Are you taking any medications? (please list) (12) Did you ever undergo TMS in the past? If so, were there any problems. (13) Did you ever undergo MRI in the past? If so, were there any 			
 body (e.g., splinters, fragments, clips, etc.)? If so, specify the type of metal. (8) Do you have an implanted neurostimulator (e.g., DBS, epidural/subdural, VNS)? (9) Do you have a cardiac pacemaker or intracardiac lines? (10) Do you have a medication infusion device? (11) Are you taking any medications? (please list) (12) Did you ever undergo TMS in the past? If so, were there any problems. (13) Did you ever undergo MRI in the past? If so, were there any 		6) Are you pregnant or is there any chance that you might be?	
 (8) Do you have an implanted neurostimulator (e.g., DBS, epidural/subdural, VNS)? (9) Do you have a cardiac pacemaker or intracardiac lines? (10) Do you have a medication infusion device? (11) Are you taking any medications? (please list) (12) Did you ever undergo TMS in the past? If so, were there any problems. (13) Did you ever undergo MRI in the past? If so, were there any 		body (e.g., splinters, fragments, clips, etc.)? If so, specify	
 (10) Do you have a medication infusion device? (11) Are you taking any medications? (please list) (12) Did you ever undergo TMS in the past? If so, were there any problems. (13) Did you ever undergo MRI in the past? If so, were there any 			
 (11) Are you taking any medications? (please list) (12) Did you ever undergo TMS in the past? If so, were there any problems. (13) Did you ever undergo MRI in the past? If so, were there any 		(9) Do you have a cardiac pacemaker or intracardiac lines?	
(12) Did you ever undergo TMS in the past? If so, were there any problems.(13) Did you ever undergo MRI in the past? If so, were there any			
problems. (13) Did you ever undergo MRI in the past? If so, were there any			
	(1		
prosents	(1	Did you ever undergo MRI in the past? If so, were there any problems.	

SINGLE-PULSE TMS ADVERSE EVENTS Seizures (very low risk with single-pulse TMS) Vasodepressor syncope (reaction to anxiety and physical discomfort) Local mild discomfort under the stimulating coil Slight tongue paraesthesias (during high-intensity TMS delivered on the midline for activation of lower limb corticospinal neurons)



For the clinical use of TMS, the **direction of the induced tissue current** is important because the **M1 is best stimulated by currents** penetrating it when **flowing in the brain in a posterior-to-anterior direction**

STANDARDS FOR CLINICAL PRACTICE RECORDING

Recording Parameters	
Band-pass filter	1-2000 Hz
Sampling frequency	4000-5000 Hz
Notch filter (50-60 Hz)	No
Impedance	< 5 ΚΩ
Screen amplificator factor	50-100 μv/div for CMT 1-2 mV/div for MEPs
Screen temporal resolution	5 ms/div for UL 10 ms/div for LL
Pre-stimulus EMG recording	50 ms
Post-stimulus recording	100 ms (400 ms for CMT)

- For proper characterization of MEP amplitudes and latency several MEPs should be recorded from homonymous (right and left) target muscles
- Bipolar surface recording electrodes (e.g., Ag/AgCl cup electrodes) are applied on the distal muscles of the hand and leg

STANDARDS FOR CLINICAL PRACTICE STIMULATION

- Each hemisphere has to be investigated separately and only the MEPs elicited in the controlateral target muscle should be analyzed
- There is no universal agreement on the preferred state of the muscle for clinical studies, but a slight tonic contraction is commonly used to increase efficacy of TMS
 - if tonic muscle contraction is employed, it is recommended that both contra and ipsilateral muscles are simultaneously contracted

• those patients who cannot perform a contraction due to hemiparesis should not be asked to unilaterally preactivate the healthy side as this would artificially induce an asymmetric MEP result

• The clinical report must state whether the MEPs were recorded with the muscle at rest or during contraction, since the latter affects only the MEP but not CMAP

• Every laboratory should establish a standard instruction and a monitoring method (e.g., acoustic or visual online feedback of EMG activity) to ensure a standardized procedure across patients

STANDARDS FOR CLINICAL PRACTICE STIMULATION

• STEP 1: Coil position

- Identify the scalp location where TMS elicits the largest single-trial MEP
- When using the large round coil with limited focality, it is feasible touse a standard positioning

procedure based on external landmarks

• Once the coil position for TMS has been defined, the rim of the coil should be marked with a pen on the scalp to maintain a constant position

- STEP 2: CMT definition
 - Individual CMT should be estimated at rest and expressed in % of the MSO
- STEP 3: Stimulation
 - Single-pulse stimulation at suprathreshold intensity (140% of resting CMT)
 - 5-6 MEPs recorded from target muscle during isometric tonic contraction
 - If the MEP amplitude appears to be reduced, it is advisable to apply 5-6 stimuli at higher stimulus intensity (**170% of resting CMT**)

Optimal stimulation depends on coil position & current direction (different for right and left M1)

STANDARDS FOR CLINICAL PRACTICE MEASUREMENT OF PERIPHERAL MOTOR CT

1) FORAMINAL ELECTROMAGNETIC STIMULATION

- The round coil is positioned over spinal roots: C7/C8 and L1/L2
- · The windings of the coil follows the orientation of target root
- The coil is placed flat on the skin and centered over body midline or 1-2 cm lateral to the spine (to stimulate spinal nerve passing foramen)
- Foraminal magnetic stimulation should use a **low stimulus intensity** which is just suprathreshold

(*rule*: the amplitude of the foraminally *induced CMAP* should have a singletrial peak-to-peak amplitude < 1 mV. If higher intensities of stimulation are used, the point of nerve stimulation will move distally, inducing an error in the estimation of PMCT)

• The CMAP evoked by foraminal magnetic stimulation is used to calculate the peripheral motor latency (PML) which corresponds to the peripheral conduction time from the neuroforamen to the muscle

• This implies that the conduction time along the very proximal section within the spinal canal is assigned to the CMCT. The resulting error in CMCT estimation depends on the length of the nerve section in the spinal canal and amounts to **0.5-1.4 ms** for cervical and **3.0-4.1** ms for lumbar spine

• This method can falsely increase CMCT in patients with nerve root lesions

10ms

PML = S





STANDARDS FOR CLINICAL PRACTICE ANALYSIS OF NEUROPHYSIOLOGICAL RECORDINGS

For clinical examination, every department using TMS should have a table of normative values for:

- MEP/CMAP ratio
- CMCT
- Resting CMT
- CSP (if needed)

in both absolute values and right-to-left differences

Normative values should be available for each muscle tested and should be divided for sex, height, decades of age

UPPER LIMB CORTICOMOTOR CONDUCTION

Abnormal value > 2.5 (conservatively 3 SD) vs control mean

Target muscle	Method	CML	PML	CMCT	References
First dorsal interossus	Cervical MS	20.6-21.2 ± 1.8*	14.0-14.9 ± 1.4*	5.8-6.5 ± 1.1*	Kloten et al. (1992)
	Cervical MS	No data	13.2 ± 1.5	No data	Britton et al. (1990)
	F-wave method	No data	14.5 ± 1.4	No data	Britton et al. (1990)
Abductor digiti minimi	Cervical MS	18.8 ± 1.2 (f)	11.8 ± 1.0	7.0 ± 0.8	Chu (1989)
	Cervical MS	19.7 ± 1.0 (m)	12.7 ± 1.1	7.1 ± 1.1	Chu (1989))
	Cervical MS		14.0 ± 1.5	6.0 ± 0.9	Claus (1990)
	Cervical MS	20.5 ± 1.2		7.0 ± 0.9	Furby et al. (1992) (21-54 years)
	F-wave method			6.1 ± 1.0	Furby et al. (1992) (21-54 years)
	F-wave method			7.2 ± 1.2	Cicinelli et al. (1997a)
	F-wave method			5.8 ± 0.8	Claus (1990)
Abductor pollicis brevis	Cervical MS	21.8 ± 1.8	14.4 ± 1.4	7.2 ± 1.8	Tabaraud et al. (1989)
	Cervical MS	21.4 ± 1.5	14.8 ± 1.2	6.6 ± 1.4	Ludolph et al. (1989)
	Cervical MS	20.2 ± 1.6		7.9 ± 2.1	Eisen and Shtybel (1990)
	F-wave method			5.66 + 0.84	Rossini et al. (1992) (16-35 years
	F-wave method			5.45 + 0.72	Rossini et al. (1992) (51-86 years
Biceps brachii	Cervical MS	10.8-11.4 ± 1.3*	6.3-6.8 ± 1.1*	$4.5 - 4.6 \pm 1.0^{\circ}$	Kloten et al. (1992)
	Cervical MS	12.5 ± 1.2		7.1 ± 1.1	Furby et al. (1992) (21-54 years)
	Cervical MS	9.4 ± 1.7		6.0 ± 1.2	Eisen and Shtybel (1990)

Cervical MS – cervical foraminal magnetic stimulation; CML – Corticomotor latency; PML – Peripheral motor latency; CMCT – Central motor conduction time. * Increase with age (age range: 19–60 years; (f) females; (m) males).

LOWER LIMB CORTICOMOTOR CONDUCTION

Normative data for the lower limb examination. Overview of published normative data on central motor conduction time (CMCT) for the lower limbs using M. tibialis anterior as target muscle. In all studies a standard circular coil and a monophasic pulse configuration was used for TMS of the M1-LEG. Data is given as mean ± SD: standard deviation.

Reference	Group description number (age range)	Central motor conduction time (lower limb)			
		Mean ± SD (ms)	Upper normal limit (ms)	Side-to-side difference (ms	
F-wave method					
Claus et al. (1991)	n = 45 (18-71 years)	9.7 ± 2.7	16.5	4.5	
Furby et al. (1992)	n = 50 (21–54 years)	9.9 ± 1.8		1	
Rossini et al. (1992)	n = 25 (16-35 years)	12.7 + 1.20		1	
	n = 40 (51 - 86 years)	12.9 + 1.69		2	
Lumbar (foraminal) elect	romagnetic stimulation				
Chu (1989)	n = 52 (17-35 years)	14.8 ± 1.1	17.6	No data	
Kloten et al. (1992)	n = 18 (19-29 years)	13.4 ± 1.9	18.2	1.6	
	n = 21 (30–59 years)	16.1 ± 1.9	18.5	2.2	
	n = 18 (>60 years)	13.4 ± 1.9	20.9	2.0	
Furby et al. (1992)	n = 50 (21–54 years)	13.8 ± 1.5		0.9	
Electrical high-voltage sti	mulation				
Claus (1990)	n = 54 (19 - 59 years)	12.5 ± 1.7	16.7	3.6	

CORTICAL SILENT PERIOD

- Time from MEP onset to the resumption of sustained EMG
- Measured during tonic voluntary activation of the target muscle
- Large number of trials (20-30 trials) estimating CSP duration
- Usually measured at a single intensity level, with insufficient information on the stimulus intensity / CSP duration relationship.
- Given these limitations, 2 strategies can be adopted to estimate the CSP duration using all CSP recordings: 5–6 trials per muscle:
 - Method I: mean CSP duration (or median) based on trial-by-trial measurements. The end of CSP is established when the EMG activity reaches or exceeds the pre-TMS baseline level for at least 50 ms. The reoccurring EMG activity marks the end of CSP.
 - Method II: rectify and average the collected 5–6 MEP/CSP traces. The end of the CSP defined as reoccurrence of voluntary EMG relative to baseline.
- Automatic algorithms based on pre-stimulus EMG (*Daskalakis et al, 2003;* Garvey et al, 2001; King et al, 2006) can be integrated in clinical practice and might help increasing CSP estimation reliability, on single trials or rectified/averaged multiple traces

